INBS Intelligent Bio Solutions Inc.
HealthcareAs of 2026-05-25
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.46
P/S
0.42
EV/EBITDA
0.32
DCF Value
$0.37
FCF Yield
-689.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
32.1%
Operating Margin
-300.3%
Net Margin
-296.8%
ROE
-174.2%
ROA
-78.1%
ROIC
-110.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 null | $1.1M | $-2.9M | $— |
| Q2 null | $896.8K | $-2.7M | $— |
| Q1 null | $1.1M | $-3.0M | $— |
| Q4 null | $843.9K | $-3.1M | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
4.24
Intelligent Bio Solutions Inc., a life sciences company, developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.